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Abstract 
Deposition of alpha-synuclein in the brain is a hallmark of Lewy body disorders. Alpha-synuclein has been con-
sidered to show prion-like properties. Prion diseases can be transmitted by the transplantation of cadaveric 
dura mater causing iatrogenic Creutzfeldt-Jakob disease. Recent observations of amyloid-β deposition in dural 
grafts support the seeding properties of amyloid-β. Here we assessed the presence of alpha-synuclein in dura 
mater samples as a potential transmissible seed source. We immunostained 32 postmortem dura mater sam-
ples; 16 cases with Lewy-body disorder (LBD) showing different pathology stages and 16 non-LBD cases for 
phosphorylated (Ser129) and disease-associated (5G4) alpha-synuclein. Disease-associated alpha-synuclein 
aggregates were identified in intradural nerve fibres and associated with a vessel in a single LBD-Braak stage 4 
case. We conclude that alpha-synuclein is detectable, although rarely, in dura mater samples in patients with 
LBD. The risk of potential transmissibility of dural alpha-synuclein deserves assessment by complementary ex-
perimental studies. 
Keywords: Alpha-synuclein; Dura mater; Lymphatic drainage; Prion; Propagation; Transmission 
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Introduction 
Neurodegenerative diseases are considered pro-
tein-misfolding disorders. As described in prion diseases, 
the host physiological protein adopts an abnormal con-
formation (seed), capable of inducing misfolding and 
aggregation of the neighboring molecules (e.g. for prion 
protein: the physiological PrPC converting to disease-
associated PrPSc, and PrPSc recruiting more PrPC). In prion 
disease, strong clinical, epidemiological and experi-
mental evidence has demonstrated human and inter-
species transmissibility of PrPSc(1). For several other 
proteins associated with neurodegenerative conditions, 
such as Amyloid-β (Aβ), Tau, alpha-synuclein, and TAR 
DNA binding protein (TDP-43), properties similar to 
those of PrP have been shown predominantly in an ex-
perimental setting (2). 
The potential of Aβ peptides to be transmitted be-
tween humans has been a topic of great interest for 
public health. Young adults with iatrogenic Creutzfeldt-
Jakob-Disease (CJD) following cadaveric pituitary-derived 
growth hormone in childhood were found to have Aβ 
deposits in the brain parenchyma and blood vessels (3, 
5, 6), as well as in iatrogenic CJD after dura grafting (4). 
Two studies have reported the presence of Aβ deposits 
in dura mater samples of postmortem brains of patients 
with Alzheimer’s disease (AD) and other neurodegenera-
tive pathologies (7, 8). Additionally, neurosurgical pro-
cedures and dural grafting during childhood or teenage 
years have been related to increased cerebral amyloid 
angiopathy (CAA) decades later (9, 10). These findings 
indicate that dura mater grafts could be also a source of 
Aβ seeds capable of inducing the aggregation of Aβ in 
the CNS of the graft recipients. 
Lewy-body disorders (LBD) and multiple system at-
rophy (MSA) are characterized by the accumulation of 
alpha-synuclein. A growing body of experimental evi-
dence supports prion-like propagation in alpha-
synucleinopathies (11-13). Observations in a small num-
ber of subjects with Parkinson`s disease (PD) treated 
with fetal mesencephalic dopaminergic grafts in the 
striatum, who years later were found to have alpha-
synuclein positive LBs in grafted neurons, first suggested 
the potential of alpha-synuclein propagation from host 
to graft cells (14, 15). While experimental studies have 
also successfully demonstrated the transmission poten-
tial of MSA alpha-synuclein in genetically modified 
mouse models (16), observations in humans argue 
against a human-to-human iatrogenic transmission of 
MSA and PD (17). Given the potential implications for 
public health, we posit that thorough assessment of the 
potential transmissibility of all neurodegenerative pro-
teinopathies is essential (18). Therefore, in this study, 
we assessed human postmortem dura mater samples, 
some of which have been previously shown to harbor Aβ 
deposits (7), for the presence of alpha-synuclein aggre-
gates, which may represent seeds with the potential of 
propagating further synucleinopathy. 
Material and methods 
Formalin-fixed and paraffin-embedded postmor-
tem tissue samples of the dura mater from the left tem-
poral and posterior region as well as cross-sections from 
the area of the superior sagittal sinus and confluence of 
sinuses (7), were cut into 5-micrometer thick sections. 
This study was approved by the Ethics Committee of the 
Medical University of Vienna. 
Brains were previously evaluated neuropathologi-
cally and a final primary diagnosis and concomitant pa-
thologies were recorded. Fixation time of dura mater 
samples ranged from 3 to 10 years. Immunohistochemis-
try of the dura mater samples was performed on an 
automated immunostainer (DAKO Autostainer Link 48, 
Glostrup, Denmark) using two different anti-alpha-
synuclein antibodies: clone 5G4 (1:4000), Roboscreen, 
Leipzig, Germany; specific for disease-associated forms 
and the phospho-specific anti-alpha-synuclein phos-
phorylated at serine 129 (Wako) (1:2000). In addition, 
we performed immunohistochemical staining to depict 
the nerve fibres within the connective tissue of the dura 
mater: anti-neurofilament protein (NFP), clone 2F11 
(1:800), DAKO; PGP 9.5 (1:100), DAKO, rabbit polyclonal; 
anti-tyrosine hydroxylase, clone 1B5 (1:200), Novocas-
tra, Newcastle, UK; and anti-phosphorylated neurofila-
ments, clone SMI31 (1:5000), former Covance Research 
Products, Princeton, NJ, USA, and for blood and lym-
phatic vascular endothelia (anti-CD34, clone QBEnd/10 
(1:100), Novocastra; and podoplanin (1:3000), rabbit 
polyclonal). DAKO Flex system (peroxidase/DAB) was 
used for visualization of antibody reactions. Samples 
were assessed blind to the neuropathological diagnosis. 
The presence or absence of each specific immunoreac-
tivity was recorded. In addition, double immunofluores-
cence combining PGP 9.5 and 5G4 antibodies and im-
munofluorescence staining with NFP and 5G4 on adja-
cent tissue sections was performed in one selected case. 
Results 
We analyzed postmortem dura mater samples 
from 32 donors (50% females) aged between 84 and 87 
years (mean 84.9) from the Vienna Transdanube Aging 
(VITA) Study (19). 
Free Neuropathology 1:6 (2020) Ellen Gelpi et al 
doi: https://doi.org/10.17879/freeneuropathology-2020-2616 page 3 of 9 
 
 
 
Case 
no. Age Gender 
Synuclein 
CNS 
(1 yes/ 0 no) 
Clinical diagnosis 
• Synuclein pathology 
in the CNS 
• Synuclein pathology 
in DMNV/vagus nerve 
Additional neuro-
pathological find-
ings 
Synuclein 
in dura 
(no.of nerves) 
Abeta patches 
in dura 
1 84 female 1 PD • LBD stage 6 
• positive AD-NP: A2, B2, C2 
negative 
(0/n.e.) negative 
2 85 female 1 vascular risk factors 
• amygdala predomi-
nant LBD 
• negative 
AD-NP: A3, B3, C3 negative (0/49) negative 
3 84 male 1 vascular risk factors • LBD stage 3 
• positive PART def + CAA 
negative 
(0/45) negative 
4 84 male 1 none 
• amygdala predomi-
nant LBD 
• negative 
AD-NP: A3, B2, C3 + 
AGD II 
negative 
(0/36) negative 
5 85 male 1 stroke, dementia 
• amygdala predomi-
nant LBD 
• negative 
AD-NP: A3, B3, C3 + 
CAA + limbic TDP43 
negative 
(0/18) POSITIVE 
6 85 female 1 vascular risk factors • LBD stage 2 
• positive 
AD-NP: A1, B2, C1 + 
AGD II + SVD 
negative 
(0/28) negative 
7 86 female 1 stroke, vascular epilepsy 
• amygdala predomi-
nant LBD 
• negative 
AD -NP: A3, B3, C3 
+ HS-TDP43 + SVD 
negative 
(0/7) negative 
8 86 female 1 dementia, vascular risk factors 
• LBD stage 4 
• positive 
AD-NP: A2, B2, C2 + 
CAA 
negative 
(0/12) negative 
9 84 male 1 
ischaemic cardiomy-
opathy, AD type 
dementia 
• amygdala predomi-
nant LBD 
• negative 
AD-NP: A3, B3, C3  negative (0/49) negative 
10 82 male 1 
PD, dementia, vas-
cular leucoencepha-
lopathy 
• LBD stage 5 
• positive 
 AD-NP: A2, B2, C1 
+ vascular 
negative 
(0/7) negative 
11 83 male 1 stroke, hypertension • LBD stage 1 
• positive mild 
AD-NP: A2, B2, C2 + 
mild CAA + vascular 
negative 
(0/10) negative 
12 85 male 1 
lung carcinoma, 
ischaemic and re-
strictive cardiomyo-
pathy 
• LBD stage 4 
• positive 
AD-NP: A2, B1, C1 + 
vascular 
POSITIVE 
(9/28) negative 
13 84 female 1 
AD type dementia, 
invasive colon carci-
noma 
• MSA 
• Negative, GCI in wm 
tracts 
MSA + AD-NP: A3, 
B3, C3 + CAA + 
TDP43 limbic 
negative 
(0/53) POSITIVE 
14 85 female 1 metastatic colon carcinoma 
• LBD stage 4 
• positive 
AD-NP: A2, B1, C2 + 
complex tauopathy 
+ TDP limbic 
negative 
(0/19) POSITIVE 
15 86 female 1 
dementia with psy-
chiatric alterations, 
oesophagus carcino-
ma  
• amygdala predomi-
nant LBD 
• positive mild 
FTLD-TDP43 type C 
+ AD-NP: A1, B1, C1 
negative 
(0/33) negative 
16 84 male 1 stroke, ischaemic cardiomyopathy 
• LBD stage 4 
• positive PART def + CAA 
negative 
(0/44) negative 
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Case 
no. Age Gender 
Synuclein 
CNS 
(1 yes/ 0 
no) 
Clinical diagnosis 
• Synuclein pathology 
in the CNS 
• Synuclein pathology 
in DMNV/vagus nerve 
Additional neuropa-
thological findings 
Synuclein 
in dura 
(no.of nerves) 
Abeta patches 
in dura 
17 84 female 0 
dementia, ischaemic 
cardiomyopathy, 
vascular risk factors, 
renal carcinoma 
0 AD-NP: A3, B3, C3 negative (0/42) negative 
18 84 male 0 
COPD, empyema, 
respiratory insufficien-
cy, abd skin melanoma 
0 AD-NP: A3, B2, C3 negative (0/41) negative 
19 86 female 0 
generalized arterio-
sclerosis, dilatative 
cardiomyopathy 
0 AD-NP: A2, B2, C2 negative (0/40) negative 
20 85 female 0 
brain contusion after 
fall, pneumonia, 
ischaemic cardiomyo-
pathy 
0 AD-NP: A3, B2, C2 + 
CAA + HS-TDP43 
negative 
(0/12) negative 
21 85 female 0 
dementia, parkinso-
nism, thyroid carci-
noma, pneumonia 
0 AD-NP: A3, B3, C3 + CAA 
negative 
(0/6) negative 
22 87 male 0 
ischaemic cardiomyo-
pathy, cardiac insuffi-
ciency 
0 AD-NP: A3, B3, C3 + CAA 
negative 
(0/17) negative 
23 86 male 0 
cardiomyopathy, 
hypertension, diabe-
tes, fall with hip 
fracture 
0 AD-NP: A2, B1, C2 + vascular 
negative 
(0/8) negative 
24 86 male 0 pancreas adenocarci-noma 0 CBD 
negative 
(0/50) negative 
25 86 female 0 
parkinsonism vs PD, 
diabetes, hypertensi-
on, dilatative cardio-
myopathy 
0 PSP + AD-NP: A2, B2, C2 + CAA 
negative 
(0/67) POSITIVE 
26 86 female 0 
dementia, pacemaker, 
hypertension, breast 
carcinoma 
0 AD-NP: A2, B2, C2 + AGD II 
negative 
(0/20) POSITIVE 
27 84 male 0 COPD, dilatative cardiomyopathy 0 
AD-NP: A2, B2, C2 + 
mild CAA + vascular 
negative 
(0/47) negative 
28 85 male 0 
ischaemic cardiomyo-
pathy, diabetes, 
hypertension 
0 AD-NP: A2, B2, C2 + CAA + AGD I  
negative 
(0/n.e.) POSITIVE 
29 85 female 0 
metastatic gastric 
adenocarcinoma, 
diabetes, hypertension 
0 AD-NP: A3, B3, C3 + CAA 
negative 
(0/34) POSITIVE 
30 87 male 0 dementia, diabetes, hypertension 0 
AD-NP: A3, B2, C2 + 
CAA + AGD II 
negative 
(0/n.e.) negative 
31 87 female 0 AD type dementia, diabetes, nephropathy 0 
AD-NP: A2, B2, C2 + 
mild CAA 
negative 
(0/38) POSITIVE 
32 83 male 0 
COPD, cardiomyopa-
thy, traumatic spinal 
cord injury, pneumo-
nia 
0 AD-NP: A3, B3, C3 + CAA + limbic TDP43 
negative 
(0/54) negative 
Table 1: Demographic and neuropathological features of the study cohort 
 
Abbreviations: AD: Alzheimer’s disease; PD: Parkinson’s disease; COPD: chronic obstructive pulmonary disease; AD-NP: Alzheimer’s 
disease neuropathological changes; CAA: cerebral amyloid angiopathy; AgD: argyrophilic grain disease; HS: hippocampal sclerosis; 
PART: primary age-related tauopathy; SVD: small vessel disease; CBD: corticobasal degeneration. n.a.: not available; n.e.: not evaluable 
due to unsteady immunoreactivity 
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These cases were analyzed in a previous study for 
the presence of Aβ deposits Neuropathological diagno-
ses included 16 cases with alpha-synuclein pathology 
(Table 1; six cases with amygdala predominant Lewy 
body pathology, one MSA case, single cases of Braak 
stage 1, stage 2, stage 3, stage 5 and stage 6, and four 
cases with Braak stage 4 of PD-related pathology) (20); 
and 16 cases without LB pathology but other neuropa-
thological conditions. Nerve fibers were detected mainly 
by NFP immunohistochemistry in all cases in variable 
distribution: large nerves surrounding large vessels (Fig. 
1A, B) or smaller nerve branches in between both dura 
layers (Fig. 1C, D). ). These patterns were also observed 
by immunofluorescence (Fig. 2). No immunoreactivity 
for tyrosine-hydroxylase could be detected. CD34 and 
podoplanin also gave negative results. 
Detailed immunohistochemical analysis of dura 
samples identified pathological alpha-synuclein aggre-
gates with the 5G4 antibody in one case. 
 
 
Figure 1: A-D: Histologic appearance of dura mater consisting of two lamellae of connective tissue. Within the connective tissue there 
are large and small vessels, which are surrounded by nerve fibres (A-D, neurofilament immunohistochemistry). Nerve fibres are also 
identified between the lamellae and within the connective tissue (arrows). E-I: Immunohistochemistry for phosphorylated alpha-
synuclein at serine 129 and for oligomeric forms with the 5G4 antibody did not show abnormal alpha-synuclein aggregates in most of 
the studied cases (Fig. 1E, F). In one case (case #12 table 1), coarse (G) and punctate (H) aggregates within nerve fibres and perivascular 
(I) aggregates were identified with the 5G4 antibody. 
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These aggregates consisted of small punctate de-
posits along nerve fibres (Fig. 1H, 2B, D), coarse aggre-
gates (Fig. 1G, 2F) and perivascular deposits (Fig. 1I, 2A). 
We observed a variable staining intensity of axons 
among the different cases and also within the same 
case, which was not related to the presence/absence of 
alpha-synuclein. This variability might have been related 
to the fixation time or tissue quality, among other po-
tential variables, so we could not reliably assess axonal 
preservation in the patient with alpha-synuclein aggre-
gates. We found no tortuous axonal profiles or axonal 
swellings. This individual was an 85-year-old male with 
coronary disease with severe and generalized athero-
sclerosis, an old myocardial infarction, as well as pulmo-
nary adenocarcinoma. No parkinsonism or dementia 
were clinically reported. Neuropathological examination 
revealed a vascular encephalopathy and Braak stage 4 
Lewy-body pathology, with only mild neurofibrillary 
pathology in the limbic system and mild neuritic plaque / 
Aβ pathology (Table 1, case 12). In the remaining cases 
included in our study, with or without CNS Lewy body 
pathology, there was a complete lack of alpha-synuclein 
immunoreactivity in dural samples applying both anti-
bodies.
 
 
Figure 2: Immunofluorescence images 
A, B: Double immunofluorescence for PGP 9.5 depicts delicate perivascular fibres (red) which focally also accumulate alpha-synuclein 
(5G4, green). Other regions show nerve fascicles with variable density of axonal profiles: some have abundant axons (B, PGP 9.5, red) 
and show only tiny alpha-synuclein accumulations (5G4, green, white arrow). C-F: In adjacent tissue sections some nerve fascicles have 
only few axons (C, NFP) while others show an intermediate density of axons (E, NFP red) with relatively abundant and coarse alpha-
synuclein aggregates (F, 5G4). 
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Discussion 
In this study, we found alpha-synuclein aggregates 
in dura mater samples from one patient with Lewy-body 
pathology (Braak stage 4) (20). Alpha-synuclein aggre-
gates were not identified in the dura mater of 31 other 
cases with different stages of LBD or in other neuro-
degenerative conditions. These findings might have 
implications for public health as well as for the under-
standing of alpha-synuclein propagation. 
Concerning public health, individuals with symp-
tomatic or prodromal alpha-synucleinopathies may un-
dergo neurosurgical interventions contacting the dura 
mater (for example, the widespread use of deep brain 
stimulation in PD). While there is still no epidemiological 
evidence of human-to-human transmission of alpha-
synuclein (17), the application of appropriate prevention 
measures will be increasingly required if experimental 
studies strengthen evidence of the potential transmissi-
bility of synucleinopathies. This further emphasizes the 
need for effective biomarkers for the early diagnosis of 
alpha-synuclein related diseases (21-24). Furthermore, 
there is a clear need for the detailed mapping of tissues 
that may harbor potential seeds. Indeed, with respect to 
the present findings, since dura mater transplants are in 
direct contact with brain tissues, they might provide an 
increased potential to propagate seeds to the recipient’s 
CNS. 
Concerning protein propagation, the dura mater 
has been a source of disease transmission in human 
prion disease (1) and is also a source for Aβ seeds (9, 
10). Recent studies support the notion that these seeds 
are able to propagate pathological proteins, even with-
out inducing the classical Alzheimer´s phenotype. How-
ever, they can lead to unexpectedly increased frequency 
of cerebral amyloid angiopathy and associated brain 
hemorrhages (9, 10). 
Propagation of human alpha-synuclein has been 
considered since the detection of alpha-synuclein aggre-
gates in grafted fetal mesencephalic neurons in PD pa-
tients (14, 15). This has subsequently been demonstrat-
ed in experimental studies (13) including inoculation of 
human substantia nigra extracts containing Lewy bodies 
into wild-type mice and macaque monkeys (26). In con-
trast, the inoculation of extracts of peripheral alpha-
synuclein from the autonomic sympathetic stellate gan-
glion did not induce pathological conversion of endoge-
nous alpha-synuclein, alpha-synuclein propagation, or 
neurodegeneration in mice (27). Thus, central and pe-
ripheral nervous system-related alpha-synuclein might 
have different propagation potential and therefore dif-
ferent transmissibility. 
The dura mater is thoroughly innervated by affer-
ent fibres arising from the ipsilateral trigeminal ganglion 
and nerve (including its ophthalmic, maxillary and man-
dibular divisions) and by sympathetic fibres arising from 
the ipsilateral superior cervical ganglion. The posterior 
cranial fossa dura mater receives sensory meningeal 
branches from the vagus and glossopharyngeal nerves. 
The sympathetic ganglion is upstream from the stellate 
ganglion, which has been shown to harbor prominent 
alpha-synuclein or Lewy-type pathology in postmortem 
studies of patients with PD and dementia with Lewy 
bodies (23, 24), along with the dorsal motor nucleus of 
the vagal nerve in the CNS (20). Therefore, it might be 
reasonable to consider that these sympathetic and para-
sympathetic fibres innervating the dura mater might also 
accumulate alpha-synuclein. Although in that particular 
case where we found alpha-synuclein in the dura mater, 
we did not have the opportunity to stain the trigeminal 
ganglion or nerve nor the stellate ganglion, we have 
previously evaluated the trigeminus nerve using im-
munostaining for alpha-synuclein. In that study we 
found alpha-synuclein immunoreactivity in two out of 
four PD/LBD cases where a total of six trigeminal nerves 
(in two cases both sides available) were examined (28). 
Alternatively, we have previously reported that the 
presence of lymphatic vessels in dura mater might be a 
drainage route for molecules from the brain parenchyma 
in neurodegenerative disorders, including alpha-
synuclein in LBD (25). Although we found discrete peri-
vascular alpha-synuclein aggregates in dura mater sam-
ples, we were not able to confirm whether these repre-
sent lymphatic vessels, possibly due to the prolonged 
fixation time of this dura mater sample (>6 years), and 
therefore this question deserves further study. 
The present study has some limitations. First, as 
mentioned above, the dura mater samples were ob-
tained after a prolonged fixation time, which may influ-
ence immunohistochemical results, not only for CD34, 
podoplanin and TH, but for phospho-synuclein as well 
(29). Therefore, the interpretation concerning the peri-
vascular association of alpha-synuclein aggregates needs 
some caution. We could also not reliably assess axonal 
preservation in the case harboring alpha-synuclein ag-
gregates. The prolonged fixation also does not allow 
complementary molecular/biochemical studies. While 
the identification of characteristic pathological aggre-
gates of alpha-synuclein with only one antibody is limit-
ing, the 5G4 antibody has shown to be a robust marker 
of early alpha-synuclein pathology, even in brains with 
prolonged fixation time (30). Second, the level of patho-
logical forms of alpha-synuclein detectable by conven-
tional immunohistochemistry may be low. Moreover, 
the analysis of the supratentorial, rather than the in-
fratentorial dura could also have been a limiting factor 
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due to differences in their innervation; however, the 
supratentorial dura mater also receives sympathetic and 
parasympathetic innervation, and thus could also be 
exposed to transport of misfolded proteins. The negative 
findings in the other LBD cases of the series might reflect 
a sampling limitation, as it was not feasible to examine 
the whole dura mater. Alternatively, the lack of staining 
could also reflect the diverse innervation of the dura and 
different pathogenic capacities of central and peripheral 
alpha-synuclein, or it could also indicate that the dura 
mater is not a primary vulnerable region for alpha-
synuclein aggregation and could be considered to be a 
low risk tissue for the accumulation of potentially 
transmissible seeds. It must be emphasized that this 
study raises a potentially important issue but is unable 
to provide a conclusion on the risk of transmission of 
alpha-synuclein via dura mater grafts or neurosurgical 
procedures. This observation would ideally be comple-
mented by experimental studies using prospectively 
collected freshly harvested, short fixed and frozen dura 
samples, including a larger cohort of patients of different 
age groups. 
Conclusion 
Disease-associated alpha-synuclein is detectable by 
conventional immunohistochemistry in postmortem 
supratentorial dura mater, here in a single patient with 
Lewy-body-type alpha-synucleinopathy in the CNS. This 
suggests propagation of alpha-synuclein from the brain 
and may indicate that dura mater could be a potential 
risk tissue for inadvertent transmission of alpha-
synuclein by dura mater grafts or surgery. Further exper-
imental and biochemical studies are needed to assess 
the risk of alpha-synuclein transmission via dura mater 
and its relationship with human disease. 
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